vs
Ecovyst Inc.（ECVT）与Ultragenyx Pharmaceutical Inc.（RARE）财务数据对比。点击上方公司名可切换其他公司
Ultragenyx Pharmaceutical Inc.的季度营收约是Ecovyst Inc.的1.0倍（$207.3M vs $199.4M），Ecovyst Inc.同比增速更快（34.0% vs 25.9%），Ecovyst Inc.自由现金流更多（$22.9M vs $-100.8M），过去两年Ultragenyx Pharmaceutical Inc.的营收复合增速更高（38.0% vs 18.7%）
Ecovyst Inc.是一家全球可持续特种材料供应商，主营高性能催化剂与功能性添加剂的研发、生产，产品服务覆盖工业制造、消费品、环保等核心领域，助力全球客户提升运营效率、降低碳排放。
Ultragenyx Pharmaceutical Inc.是一家总部位于美国的生物制药企业，专注于研发罕见病和超罕见遗传病的创新治疗方案，这类疾病目前大多无获批疗法，存在大量未被满足的临床需求。公司覆盖生物制剂、小分子药物、基因疗法、反义寡核苷酸及mRNA等多种药物技术平台，研发管线涵盖骨骼、内分泌、代谢、肌肉及中枢神经系统疾病领域。
ECVT vs RARE — 直观对比
营收规模更大
RARE
是对方的1.0倍
$199.4M
营收增速更快
ECVT
高出8.1%
25.9%
自由现金流更多
ECVT
多$123.7M
$-100.8M
两年增速更快
RARE
近两年复合增速
18.7%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $199.4M | $207.3M |
| 净利润 | — | $-128.6M |
| 毛利率 | 23.4% | — |
| 营业利润率 | 10.9% | -54.7% |
| 净利率 | — | -62.0% |
| 营收同比 | 34.0% | 25.9% |
| 净利润同比 | — | 3.5% |
| 每股收益（稀释后） | $0.06 | $-1.28 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ECVTRARE
| Q4 25 | $199.4M | $207.3M | ||
| Q3 25 | $204.9M | $159.9M | ||
| Q2 25 | $176.1M | $166.5M | ||
| Q1 25 | $143.1M | $139.3M | ||
| Q4 24 | $148.9M | $164.6M | ||
| Q3 24 | $153.9M | $139.5M | ||
| Q2 24 | $154.0M | $147.0M | ||
| Q1 24 | $141.6M | $108.8M |
净利润ECVTRARE
| Q4 25 | — | $-128.6M | ||
| Q3 25 | $-79.3M | $-180.4M | ||
| Q2 25 | $6.0M | $-115.0M | ||
| Q1 25 | $-3.6M | $-151.1M | ||
| Q4 24 | — | $-133.2M | ||
| Q3 24 | $14.3M | $-133.5M | ||
| Q2 24 | $8.3M | $-131.6M | ||
| Q1 24 | $1.2M | $-170.7M |
毛利率ECVTRARE
| Q4 25 | 23.4% | — | ||
| Q3 25 | 25.4% | — | ||
| Q2 25 | 22.8% | — | ||
| Q1 25 | 13.3% | — | ||
| Q4 24 | 28.9% | — | ||
| Q3 24 | 29.3% | — | ||
| Q2 24 | 27.3% | — | ||
| Q1 24 | 23.5% | — |
营业利润率ECVTRARE
| Q4 25 | 10.9% | -54.7% | ||
| Q3 25 | 13.8% | -106.9% | ||
| Q2 25 | 9.0% | -64.8% | ||
| Q1 25 | -0.7% | -102.6% | ||
| Q4 24 | 15.1% | -74.3% | ||
| Q3 24 | 17.9% | -94.6% | ||
| Q2 24 | 14.1% | -79.1% | ||
| Q1 24 | 9.5% | -151.9% |
净利率ECVTRARE
| Q4 25 | — | -62.0% | ||
| Q3 25 | -38.7% | -112.8% | ||
| Q2 25 | 3.4% | -69.0% | ||
| Q1 25 | -2.5% | -108.5% | ||
| Q4 24 | — | -80.9% | ||
| Q3 24 | 9.3% | -95.7% | ||
| Q2 24 | 5.4% | -89.5% | ||
| Q1 24 | 0.9% | -156.8% |
每股收益（稀释后）ECVTRARE
| Q4 25 | $0.06 | $-1.28 | ||
| Q3 25 | $-0.69 | $-1.81 | ||
| Q2 25 | $0.05 | $-1.17 | ||
| Q1 25 | $-0.03 | $-1.57 | ||
| Q4 24 | $-0.26 | $-1.34 | ||
| Q3 24 | $0.12 | $-1.40 | ||
| Q2 24 | $0.07 | $-1.52 | ||
| Q1 24 | $0.01 | $-2.03 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $197.2M | $421.0M |
| 总债务越低越好 | $392.6M | — |
| 股东权益账面价值 | $603.4M | $-80.0M |
| 总资产 | $1.3B | $1.5B |
| 负债/权益比越低杠杆越低 | 0.65× | — |
8季度趋势，按日历期对齐
现金及短期投资ECVTRARE
| Q4 25 | $197.2M | $421.0M | ||
| Q3 25 | $82.0M | $202.5M | ||
| Q2 25 | $69.6M | $176.3M | ||
| Q1 25 | $127.5M | $127.1M | ||
| Q4 24 | $131.4M | $174.0M | ||
| Q3 24 | $123.5M | $150.6M | ||
| Q2 24 | $83.3M | $480.7M | ||
| Q1 24 | $103.1M | $112.3M |
总债务ECVTRARE
| Q4 25 | $392.6M | — | ||
| Q3 25 | $854.8M | — | ||
| Q2 25 | $856.6M | — | ||
| Q1 25 | $859.0M | — | ||
| Q4 24 | $860.8M | — | ||
| Q3 24 | $862.7M | — | ||
| Q2 24 | $862.4M | — | ||
| Q1 24 | $866.2M | — |
股东权益ECVTRARE
| Q4 25 | $603.4M | $-80.0M | ||
| Q3 25 | $607.9M | $9.2M | ||
| Q2 25 | $692.4M | $151.3M | ||
| Q1 25 | $698.7M | $144.2M | ||
| Q4 24 | $700.5M | $255.0M | ||
| Q3 24 | $729.4M | $346.8M | ||
| Q2 24 | $717.3M | $432.4M | ||
| Q1 24 | $711.4M | $140.3M |
总资产ECVTRARE
| Q4 25 | $1.3B | $1.5B | ||
| Q3 25 | $1.7B | $1.2B | ||
| Q2 25 | $1.8B | $1.3B | ||
| Q1 25 | $1.8B | $1.3B | ||
| Q4 24 | $1.8B | $1.5B | ||
| Q3 24 | $1.8B | $1.5B | ||
| Q2 24 | $1.8B | $1.6B | ||
| Q1 24 | $1.8B | $1.3B |
负债/权益比ECVTRARE
| Q4 25 | 0.65× | — | ||
| Q3 25 | 1.41× | — | ||
| Q2 25 | 1.24× | — | ||
| Q1 25 | 1.23× | — | ||
| Q4 24 | 1.23× | — | ||
| Q3 24 | 1.18× | — | ||
| Q2 24 | 1.20× | — | ||
| Q1 24 | 1.22× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $41.8M | $-99.8M |
| 自由现金流经营现金流 - 资本支出 | $22.9M | $-100.8M |
| 自由现金流率自由现金流/营收 | 11.5% | -48.6% |
| 资本支出强度资本支出/营收 | 9.4% | 0.5% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $69.9M | $-472.0M |
8季度趋势，按日历期对齐
经营现金流ECVTRARE
| Q4 25 | $41.8M | $-99.8M | ||
| Q3 25 | $55.3M | $-91.4M | ||
| Q2 25 | $33.0M | $-108.3M | ||
| Q1 25 | $10.3M | $-166.5M | ||
| Q4 24 | $43.5M | $-79.3M | ||
| Q3 24 | $59.9M | $-67.0M | ||
| Q2 24 | $10.0M | $-77.0M | ||
| Q1 24 | $36.5M | $-190.7M |
自由现金流ECVTRARE
| Q4 25 | $22.9M | $-100.8M | ||
| Q3 25 | $53.2M | $-92.7M | ||
| Q2 25 | $7.8M | $-110.7M | ||
| Q1 25 | $-14.0M | $-167.8M | ||
| Q4 24 | $30.9M | $-79.5M | ||
| Q3 24 | $53.6M | $-68.6M | ||
| Q2 24 | $-9.3M | $-79.0M | ||
| Q1 24 | $19.1M | $-193.9M |
自由现金流率ECVTRARE
| Q4 25 | 11.5% | -48.6% | ||
| Q3 25 | 26.0% | -58.0% | ||
| Q2 25 | 4.4% | -66.5% | ||
| Q1 25 | -9.8% | -120.5% | ||
| Q4 24 | 20.7% | -48.3% | ||
| Q3 24 | 34.9% | -49.2% | ||
| Q2 24 | -6.1% | -53.7% | ||
| Q1 24 | 13.5% | -178.2% |
资本支出强度ECVTRARE
| Q4 25 | 9.4% | 0.5% | ||
| Q3 25 | 1.0% | 0.8% | ||
| Q2 25 | 14.4% | 1.5% | ||
| Q1 25 | 16.9% | 1.0% | ||
| Q4 24 | 8.5% | 0.1% | ||
| Q3 24 | 4.1% | 1.2% | ||
| Q2 24 | 12.5% | 1.4% | ||
| Q1 24 | 12.3% | 3.0% |
现金转化率ECVTRARE
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | 5.52× | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 4.21× | — | ||
| Q2 24 | 1.20× | — | ||
| Q1 24 | 29.90× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ECVT
| Industrial Mining Automotive | $101.3M | 51% |
| Regeneration And Treatment Services | $90.0M | 45% |
| Other | $8.1M | 4% |
RARE
| Royalty | $105.6M | 51% |
| Products | $101.7M | 49% |
